ClinicalTrials.gov record
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

ClinicalTrials.gov ID: NCT06858813

Public ClinicalTrials.gov record NCT06858813. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 11:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer

Study identification

NCT ID
NCT06858813
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
AbbVie
Industry
Enrollment
232 participants

Conditions and interventions

Interventions

  • ABBV-324 Drug
  • Lenvatinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 13, 2025
Primary completion
Aug 31, 2030
Completion
Aug 31, 2030
Last update posted
Mar 24, 2026

2025 – 2030

United States locations

U.S. sites
10
U.S. states
6
U.S. cities
10
Facility City State ZIP Site status
City of Hope National Medical Center /ID# 270526 Duarte California 91010 Recruiting
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 276120 Irvine California 92618 Recruiting
USC Norris Comprehensive Cancer Center /ID# 271573 Los Angeles California 90033 Recruiting
UC Irvine Medical Center /ID# 270507 Orange California 92868-3201 Recruiting
UCLA - Santa Monica /ID# 275995 Santa Monica California 90404 Recruiting
University of Chicago Medical Center /ID# 270517 Chicago Illinois 60637 Recruiting
Washington University /ID# 275757 St Louis Missouri 63110 Recruiting
Memorial Sloan Kettering Cancer Center /ID# 271228 New York New York 10021-3459 Recruiting
Thomas Jefferson University Sidney Kimmel Cancer Center /ID# 276269 Philadelphia Pennsylvania 19107 Recruiting
SCRI Oncology Partners /ID# 272750 Nashville Tennessee 37203 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06858813, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 24, 2026 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06858813 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →